miR-23b as a potential tumor suppressor and its regulation by DNA methylation in cervical cancer.

Infect Agent Cancer

Laboratorio de Investigación Clínica, Unidad Académica de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Av. Lázaro Cárdenas S/N, Ciudad Universitaria, Colonia La Haciendita, C.P. 39089 Chilpancingo, Guerrero México.

Published: December 2015

AI Article Synopsis

  • The study investigates how methylation affects the expression of miR-23b, a molecule linked to cancer, in cervical cancer cell lines and tissues, focusing on HPV16-positive samples.
  • Results show that higher methylation levels lead to lower expression of miR-23b in specific cell lines, and treatment with a methylation inhibitor can reverse this effect.
  • Additionally, decreased expression of miR-23b correlates with more severe lesions and significantly increases the risk of developing cervical cancer in women with premalignant conditions.

Article Abstract

Background: The aberrant expression of miR-23b is involved in the development and progression of cancer. The aim of this study was to evaluate the potential role of methylation in the silencing of miR-23b in cervical cancer cell lines and to determine its expression in stages of malignant progression and in cervical cancer tissues HPV16-positive.

Methods: The methylation of the miR-23b promoter was determined in HeLa, SiHa, CaSki and C33A cells using a Human Cancer miRNA EpiTectMethyl II Signature PCR Array®. The cells were treated with 5-Aza-2'-deoxycytidine, and the expression of miR-23b, uPa, c-Met and Zeb1 was determined by qRT-PCR. miR-92a and GAPDH were used as controls. The expression of miR-23b was determined in cervical scrapes and biopsies of women without squamous intraepithelial lesions, with precursor lesions and with cervical cancer, all were HPV16-positive. The Fisher exact and Mann-Whitney tests were used to compare the differences of the expression of miR-23b, uPa, c-Met and Zeb1 among cell groups, and the difference among patients, respectively. The association between the expression of miR-23b and cervical cancer was determined by logistic regression with a confidence level of 95 %. A value of p < 0.05 was considered statistically significant.

Results: In C33A, HeLa and CaSki cells, methylation was associated with decreased expression of miR-23b. After treatment with 5-Aza-CdR, the expression of miR-23b increased in all cell lines and the expression of c-Met decreased in HeLa cells, while uPa and Zeb1 decreased in C33A and CaSki cells. In SiHa cells the expression of uPa, c-Met and Zeb1 increased. The expression of miR-23b decreased in relation to the increase in the severity of the lesion and was significantly lower in cervical cancer. In women with premalignant lesions HPV16-positive, decreased levels of miR-23b increased the risk of cervical cancer (OR = 36, 95 % CI = 6.7-192.6, p < 0.05).

Conclusions: The results suggest that the expression of miR-23b is regulated by the methylation of its promoter and is possible that this microRNA influence the expression of uPa, c-Met and Zeb1 in cervical cancer cells lines. In women with premalignant lesions and cervical cancer infected with HPV16, the expression level of miR-23b agree with a tumor suppressor gene.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4663735PMC
http://dx.doi.org/10.1186/s13027-015-0037-6DOI Listing

Publication Analysis

Top Keywords

cervical cancer
20
expression mir-23b
20
mir-23b
8
mir-23b cervical
8
mir-23b upa
8
upa c-met
8
c-met zeb1
8
cancer
7
cervical
6
expression
6

Similar Publications

Objectives: To assess the usefulness of sentinel lymph node biopsy (SLNB) in patients with early-stage oral squamous cell carcinoma (OSCC).

Materials And Methods: Seventy-five patients (mean age 62 years) diagnosed with cT1-2 N0 underwent SLNB with Tc, lymphoscintigraphy/SPECT-CT, and gamma probe detection with intraoperative histological examination of the resected sentinel lymph nodes (SLNs). Elective neck dissection was performed during the same surgical procedure of primary tumor resection when malignant deposits were detected microscopically.

View Article and Find Full Text PDF

Unlabelled: Cervical cancer screening can effectively reduce the disease burden. In China, the current cervical cancer screening guidelines do not provide separate screening recommendations for women living with HIV (WLWH) to account for their increased risk. We developed a comprehensive individual-based simulation model to provide evidence to support tailored cervical cancer screening programs for WLWH in Guangxi, a region with a high prevalence of HIV in China.

View Article and Find Full Text PDF

Background Cervical cancer is the fourth most common cancer among women with significant global disparities in disease burden. In lower-resource settings, where routine screening is uncommon, delays in diagnosis and treatment contribute to morbidity and mortality. Understanding care delays may inform strategies to decrease time to treatment, improving patient outcomes.

View Article and Find Full Text PDF

B7-H3 (CD276), a member of the B7-family of immune checkpoint proteins, has been shown to have immunological and non-immunological effects promoting tumorigenesis [1, 2] and expression correlates with poor prognosis for many solid tumors, including cervical, ovarian and breast cancers [3-6]. We recently identified a tumor-cell autochthonous tumorigenic role for dimerization of the 4Ig isoform of B7-H3 (4Ig-B7-H3) [7], where 4Ig-B7-H3 dimerization activated tumor-intrinsic cellular proliferation and tumorigenesis pathways, providing a novel opportunity for therapeutic intervention. Herein, a live cell split-luciferase complementation strategy was used to visualize 4Ig-B7-H3 homodimerization in a high-throughput small molecule screen (HTS) to identify modulators of this protein-protein interaction (PPI).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!